At the 2026 Science of Skin Summit, Allergan Aesthetics, an AbbVie company, presented its latest research on aging, regenerative aesthetics, and exosome-based skincare. The company introduced the FACTS Principles, a scientific framework by SkinMedica® to ensure consistent evaluation of exosome skincare products, focusing on formulation, stability, safety, and clinical evidence. This initiative aims to promote transparency and rigorous scientific standards in the emerging field of exosome skincare, which holds promise for skin longevity and biological function. Allergan's R&D leaders also shared insights from over 25 years of research and numerous clinical studies, emphasizing evidence-based innovation in skincare.
Following Allergan Aesthetics' presentation at the 2026 Science of Skin Summit, AbbVie Inc (ABBV) shares show stability on Pluang, priced at USD 261.69 with no change in the last day as of Sep 15, 2026 19:14 WIB. The stock remains close to its 52-week high of USD 265.97, reflecting steady investor interest in AbbVie's health sector innovations.
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16...
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
